K2 PRINCIPAL FUND L.P. 13D and 13G filings for ARS Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-13 4:32 pm Purchase |
2022-12-31 | 13G | ARS Pharmaceuticals, Inc. SPRY |
K2 PRINCIPAL FUND L.P. | 2,045,348 2.200% |
138,730 (+7.28%) |
Filing |
| 2022-07-15 6:03 pm Purchase |
2022-07-13 | 13G | ARS Pharmaceuticals, Inc. SPRY |
K2 PRINCIPAL FUND L.P. | 1,906,618 5.410% |
1,906,618 (New Position) |
Filing |